Page last updated: 2024-09-05

jujuboside a and Lung Neoplasms

jujuboside a has been researched along with Lung Neoplasms in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	1 (100.00)	2.80

Authors

Authors	Studies
Chen, Y; Huang, Q; Huang, Y; Huang, Z; Liu, Z; Lu, L; Qi, X; Wang, W; Wang, Y	1

Other Studies

1 other study(ies) available for jujuboside a and Lung Neoplasms

Article	Year
The novel FAT4 activator jujuboside A suppresses NSCLC tumorigenesis by activating HIPPO signaling and inhibiting YAP nuclear translocation. Pharmacological research, 2021, Volume: 170 Topics: Active Transport, Cell Nucleus; Animals; Antineoplastic Agents, Phytogenic; Cadherins; Carcinoma, Non-Small-Cell Lung; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Cellular Senescence; Hippo Signaling Pathway; Humans; Lung Neoplasms; Mice; Saponins; Tumor Suppressor Proteins; YAP-Signaling Proteins	2021

Article

Year

The novel FAT4 activator jujuboside A suppresses NSCLC tumorigenesis by activating HIPPO signaling and inhibiting YAP nuclear translocation.

Pharmacological research, 2021, Volume: 170

Topics: Active Transport, Cell Nucleus; Animals; Antineoplastic Agents, Phytogenic; Cadherins; Carcinoma, Non-Small-Cell Lung; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Cellular Senescence; Hippo Signaling Pathway; Humans; Lung Neoplasms; Mice; Saponins; Tumor Suppressor Proteins; YAP-Signaling Proteins

2021